Table 3 GRADE evaluation of the studies
Certainty assessment | № of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
№ of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | nab-paclitaxel | sb-taxanes | Relative(95% CI) | Absolute(95% CI) | ||
pCR (assessed with: ypT0 ypN0) | ||||||||||||
5 | observational studies | not serious | not serious | not serious | not serious | none | 429/1069 (40.1%) | 333/1065 (31.3%) | OR 1.52(1.27 to 1.83) | 96 more per 1000(from 54 more to 142 more) | ⨁⨁◯◯LOW | CRITICAL |
pCR (assessed with: ypT0/is ypN0) | ||||||||||||
5 | observational studies | not serious | not serious | not serious | not serious | none | 379/1140 (33.2%) | 315/1195 (26.4%) | OR 1.40(1.17 to 1.68) | 70 more per 1000(from 32 more to 112 more) | ⨁⨁◯◯LOW | CRITICAL |
ORR | ||||||||||||
4 | observational studies | not serious | not serious | not serious | serious a | none | 832/1057 (78.7%) | 848/1116 (76.0%) | OR 1.19(0.97 to 1.46) | 30 more per 1000(from 6 fewer to 62 more) | ⨁◯◯◯VERY LOW | IMPORTANT |
OS | ||||||||||||
2 | randomised trials | not serious | not serious | not serious | serious a | none | 106/846 (12.5%) | 130/819 (15.9%) | OR 0.79(0.60 to 1.04) | 29 fewer per 1000(from 57 fewer to 5 more) | ⨁⨁⨁◯MODERATE | IMPORTANT |
EFS | ||||||||||||
2 | randomised trials | not serious | not serious | not serious | not serious | none | 952 participants | 949 participants | HR 0.69(0.57 to 0.85)[EFS] | -- per 1000(from -- to --) | ⨁⨁⨁⨁HIGH | IMPORTANT |
– | 0.0% | -- per 1000(from -- to --) | ||||||||||